Pediatric Nephrology

, Volume 21, Issue 10, pp 1434–1439 | Cite as

Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients

  • Wacharee Seeherunvong
  • Obioma Nwobi
  • Carolyn L. AbitbolEmail author
  • Jayanthi Chandar
  • José Strauss
  • Gastón Zilleruelo
Original Article


Secondary hyperparathyroidism (SHPT) remains a treatment dilemma in pediatric dialysis patients. Recent experience with paricalcitol (P), a vitamin D analogue, in adults with SHPT has shown equal efficacy and improved survival compared to traditional treatment with calcitriol (C). We present our experience with (C) compared to (P) treatment in our pediatric dialysis patients with SHPT. Twenty-one patients (mean age 11.5±5 years) with SHPT (intact parathyroid hormone (iPTH) averaging 1,228±496 pg/ml) were studied. Seventeen received (C) followed by (P); while an additional four were treated with either (C=1) or (P=3) alone. After 26±8 weeks, average percent (%) decrease in iPTH was similar with (C) and (P) (−60.4±34% versus −65.4±28%, respectively; p=0.6). In the (P) group, the effective dose in children was greater than in adult trials based on kilogram weight. Episodes of hypercalcemia between the treatment groups were not different. However, episodes of elevated calcium × phosphorus product (Ca×P)≥70 mg2/dl2 occurred more frequently in the (C) group (odds ratio=1.5; p=0.01). Paricalcitol appears to be safe and effective in pediatric patients. Data suggest that dosing should be gauged according to degree of SHPT. This should serve as impetus for future pharmacokinetic studies in pediatric dialysis patients.


Paricalcitol Calcitriol Hyperparathyroidism Children Young adults Hemodialysis 



This study was supported in part by a grant from Florida’s Department of Health, Children’s Medical Services.


  1. 1.
    National Kidney Foundation (2005) K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46:S1–S103Google Scholar
  2. 2.
    Salusky I (2005) Are new Vitamin D analogues in renal disease superior to calcitriol? Pediatr Nephrol 20:393–398CrossRefGoogle Scholar
  3. 3.
    Sanchez CP (2003) Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment. Pediatr Drugs 5:763–776CrossRefGoogle Scholar
  4. 4.
    Salusky IB, Fine RN, Kangarloo H, Gold R, Paunier L, Goodman WG, Brill JE, Gilli G, Slatopolsky E, Coburn JW (1987) “High-dose” calcitriol for control of renal osteodystrophy in children on CAPD. Kidney Int 32:89–95CrossRefGoogle Scholar
  5. 5.
    Mathias R, Salusky I, Harman W, Paredes A, Emans J, Segre G, Goodman W (1993) Renal bone disease in pediatric and young adult patients on hemodialysis in a children’s hospital. J Am Soc Nephrol 3:1938–1946PubMedGoogle Scholar
  6. 6.
    Slatopolsky E, Brown A, Dusso A (1999) Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 73:S14–S19CrossRefGoogle Scholar
  7. 7.
    Llach F, Velasquez Forero F (2001) Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 38:S20–S33CrossRefGoogle Scholar
  8. 8.
    Greenbaum L, Grenda R, Qiu P, Restaino I, Wojtak A, Paredes A, Benador N, Melnick JZ, Williams LA, Salusky IB (2005) Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol 20:622–630CrossRefGoogle Scholar
  9. 9.
    Cano F, Delucchi A, Wolff E, Rodriguez E, Fuentes A (1995) Calcitriol oral pulse therapy in children with renal osteodystrophy. Pediatr Nephrol 9:606–608CrossRefGoogle Scholar
  10. 10.
    Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ (1989) Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274–279CrossRefGoogle Scholar
  11. 11.
    Quarles LD, Yohay DA, Carroll BA, Spritzer CF, Minda SA, Bartholomay D, Lobaugh BA (1994) Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45:1710–1721CrossRefGoogle Scholar
  12. 12.
    Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GB, Salusky IR (1994) Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160–1166CrossRefGoogle Scholar
  13. 13.
    Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J (1998) 19-nor-1-α-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:1427–1432PubMedGoogle Scholar
  14. 14.
    Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, Soltanek C (2001) A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 56:315–323PubMedGoogle Scholar
  15. 15.
    Melnick JZ, Kommala D, Mattingly S, Amdahl M, Greenbaum WL (2004) Paricalcitol and calcitriol in treating SHPT children: a comparison of 2 studies. St. Louis, MO, GPRD, Abbott Laboratories, Abbott Park, IL; Pediatrics Medical College of Wisconsin, Milwaukee, WI [Abstract]. J Am Soc Nephrol SU-PO939Google Scholar
  16. 16.
    Llach F, Yudd M (2001) Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 38(5Suppl 5):S45–S50CrossRefGoogle Scholar
  17. 17.
    Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E (1998) Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis 32:S48–S54CrossRefGoogle Scholar
  18. 18.
    Sprague SM, Llach F, Amdahl M, Tacetta C, Batlle D (2003) Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483–1490CrossRefGoogle Scholar
  19. 19.
    Coyne DW, Grieff M, Ahya SN, Giles K, Norwood K, Slatopolsky E (2002) Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 40:1283–1288CrossRefGoogle Scholar
  20. 20.
    Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus M, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456CrossRefGoogle Scholar
  21. 21.
    Korkor AB (1987) Reduced binding of 1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 316:1573–1577CrossRefGoogle Scholar
  22. 22.
    Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y (1993) Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92:1436–1443CrossRefGoogle Scholar
  23. 23.
    Carling T, Rastad J, Szabo E, Westin G, Akerstrom G (2000) Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. J Clin Endocrinol Metab 85:2000–2003PubMedGoogle Scholar
  24. 24.
    Martin KJ, Gonzalez E, Lindberg JS, Taccetta C, Amdahl M, Malhotra K, Llach F (2001) Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am J Kidney Dis 38:S57–S63CrossRefGoogle Scholar
  25. 25.
    Kuizon D, Goodman W, Juppner H, Boechat I, Nelson P, Gales B, Salusky IB (1998) Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53:205–211CrossRefGoogle Scholar
  26. 26.
    Sanchez CP, He YZ (2005) Daily or intermittent calcitriol administration during growth hormone therapy in rats with renal failure and advanced secondary hyperparathyroidism. J Am Soc Nephrol 16:929–938CrossRefGoogle Scholar
  27. 27.
    Paczyk-Tomaszewska M, Ziókowska H, Debinski A, Sieniawska M (2000) Vitamin D metabolite requirements in dialysed children receiving recombinant human growth hormone. Nephrol Dial Transplant 15:375–378CrossRefGoogle Scholar
  28. 28.
    US Government (2006) VISN 21 Criteria for non-formulary use of paricalcitol. US Department of Veterans Affairs, USAGoogle Scholar
  29. 29.
    Dobrez D, Mathes A, Amdahl M, Marx S, Melnick J, Sprague S (2004) Paricalcitol-treated patients experience improved hospitalization outcomes compared to calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 19:1174–1181CrossRefGoogle Scholar

Copyright information

© IPNA 2006

Authors and Affiliations

  • Wacharee Seeherunvong
    • 1
  • Obioma Nwobi
    • 2
  • Carolyn L. Abitbol
    • 2
    Email author
  • Jayanthi Chandar
    • 2
  • José Strauss
    • 2
  • Gastón Zilleruelo
    • 2
  1. 1.Division of Pediatric Nephrology, Department of PediatricsRamathibodi Hospital, Mahidol UniversityBangkokThailand
  2. 2.Division of Pediatric Nephrology, Department of PediatricsUniversity of Miami/Holtz Children’s HospitalMiamiUSA

Personalised recommendations